Anpheros Search · Treatment

Atogepant

Also known as: Aquipta · Qulipta

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, atogepant is indicated for the acute treatment of migraine with or without aura in adults, and for the prophylaxis of migraine in adults who have at least 4 migraine days per month. In the United States, it is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. Atogepant has an approved use for the condition of migraine.

From: Source: European Medicines Agency (EMA), Aquipta — EPAR, 25/08/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
2571813 atogepant
EMA
EMEA/H/C/005871

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Aquipta

Aquipta is indicated for: - acute treatment of migraine with or without aura in adults - prophylaxis of migraine in adults who have at least 4 migraine days per month.

Source: European Medicines Agency (EMA), Aquipta — EPAR, 25/08/2026. © European Medicines Agency.

Document date: 25/08/2026 · Official document →

FDA (USA) Qulipta

1 INDICATIONS AND USAGE QULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 )

Data provided by the U.S. Food and Drug Administration.

Document date: 20250930 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Atogepant approved for in the European Union?

Aquipta is indicated for: - acute treatment of migraine with or without aura in adults - prophylaxis of migraine in adults who have at least 4 migraine days per month. (Source: European Medicines Agency (EMA), Aquipta — EPAR, 25/08/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Data provided by the U.S. Food and Drug Administration.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Aquipta — EPAR, 25/08/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →